Declining Competitiveness Due to Delays in New Product Development
First written in FY2019. 3 of 7 entries say "Restated". Latest entry: FY2022.
The whole theme swung hardest in 2025: 3 of 24 companies on the "Worse" side.
6 other companies' latest entry also says "Mitigated".
- FY2022MitigatedAnnual report
「The Board of Directors is also strengthening its monitoring of the status of new product development.」
As measures to address the risk of delays in new product development, the Company specified increased allocation of human resources, joint research, strengthening the development structure and enhanced monitoring of progress by the Board of Directors. - FY2021MitigatedAnnual report
「To address the above risk, the Group is increasing the allocation of human resources to new product development, focusing on developing new products that meet customer and market needs, and promoting joint research with external research institutions and new research initiatives aimed at contributing to a sustainable society. The Group is also working to strengthen its development structure in order to create new products continuously and quickly in growth markets going forward.」
The Group specified the allocation of human resources, joint research with external research institutions and strengthening the development structure as measures to address the risk of delays in new product development. - FY2020MaterialisedAnnual report
「However, although the impact of the spread of COVID-19 on Group sales was limited, worsening market conditions, delays in developing new products and other factors caused sales to fall 8.3% year on year to ¥11,607 million.」
The delay in new product development was identified as an actual factor behind the decline in full-year revenue, indicating that the risk of delays in new product development had materialized. - FY2020-Q3RestatedAnnual report
「During the first nine months of the current consolidated fiscal year, there were no new business or other risks, and no significant changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company states that there have been no material changes regarding the risk of loss of competitiveness due to delays in new product development. - FY2020-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no new business or other risks, and no significant changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company states that there have been no material changes regarding the risk of loss of competitiveness due to delays in new product development. - FY2020-Q1RestatedAnnual report
「During the first quarter of the current consolidated fiscal year, there were no new business or other risks, and no significant changes to the business and other risks described in the securities report for the previous fiscal year.」
The Company states that there have been no material changes regarding the risk of loss of competitiveness due to delays in new product development. - FY2019First statedAnnual report
「The Group conducts research and development activities to create new products continuously and quickly. However, if new product development is delayed, the Group may lose market competitiveness, which could affect its business results and financial condition.」
The risk that delays in new product development could affect market competitiveness, business results and financial condition was disclosed independently for the first time.